Showing results (1-10 of 273) with videos related to
Sort By:
Pageof 28
Discovery Medicine|October 1, 2009
Ghrelin: friend or foe for neuroinflammationSachiko Miyake, Takashi YamamuraCurrent Drug Targets. Immune, Endocrine and Metabolic Disorders|September 24, 2005
Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseasesSachiko Miyake, Takashi YamamuraJournal of Neuroimmunology|August 6, 2018
Gut environmental factors and multiple sclerosisSachiko Miyake, Takashi YamamuraInternational Reviews of Immunology|April 25, 2007
Therapeutic potential of CD1d-restricted invariant natural killer T cell-based treatment for autoimmune diseasesSachiko Miyake, Takashi YamamuraCurrent Medicinal Chemistry|October 16, 2008
Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapyManabu Araki, Sachiko Miyake, Takashi YamamuraModern Rheumatology|January 7, 2014
Potential of targeting natural killer T cells for the treatment of autoimmune diseasesSachiko Miyake, Asako Chiba, Takashi YamamuraJournal of Immunology (Baltimore, Md. : 1950)|October 4, 2006
Differential expression of CD11c by peripheral blood NK cells reflects temporal activity of multiple sclerosisToshimasa Aranami, Sachiko Miyake, Takashi YamamuraResults and Problems in Cell Differentiation|July 8, 2009
Role of NK cells and invariant NKT cells in multiple sclerosisKaori Sakuishi, Sachiko Miyake, Takashi YamamuraNihon Rinsho Men'Eki Gakkai Kaishi = Japanese Journal of Clinical Immunology|July 1, 2014
[Experimental autoimmune encephalomyelitis: crosstalk with immunology and therapy]Youwei Lin, Sachiko Miyake, Takashi YamamuraEuropean Journal of Immunology|March 5, 2003
Heterozygous null mutation of myelin P0 protein enhances susceptibility to autoimmune neuritis targeting P0 peptideKatsuichi Miyamoto, Sachiko Miyake, Melitta Schachner, et al.Pageof 28